Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
BIO comments respond to the Centers for Medicare and Medicaid Services' call for input on ways to improve the Medicare Part D program.
Express Scripts is losing its biggest customer, which could be a sign that plan sponsors are looking for more control over their pharmacy spending -- bad news for the big PBMs but good news for biopharma?
Price increases generated 100% of net US earnings growth at major biopharma firms in 2016, according to investment analyst report assessing threat of continued pricing pressure.
Former FDA Commissioner von Eschenbach and Project HOPE's Wilensky offer related views on how the government could more proactively promote competition with drugs like Shkreli's Daraprim.
Patient groups raise concerns that states may not be able to monitor formularies for discrimination, limiting patient access to drug coverage.
FDA commissioner-nominee Scott Gottlieb is expected to steer clear of pricing issues at the agency, despite his reputation as a thought leader on the issue.